CERTOLIZUMAB PEGOL IS EFFECTIVE IN UVEITIS ASSOCIATED TO SPONDYLOARTHRITIS REFRACTORY TO OTHER TUMOUR NECROSIS FACTOR INHIBITORS

被引：4
|
作者：
Hernandez, M. V. [1 ]
Mesquida, M. [2 ]
Llorens, V. [2 ]
de la Maza, M. Sainz [2 ]
Blanco, R. [3 ]
Calvo, V. [3 ]
Maiz, O. [4 ]
Blanco, A. [5 ]
Urruticoechea, A. [6 ]
Jimenez de Aberasturi, J. R. D. D. [7 ]
Ahijado, P. [8 ]
Judez, E. [9 ]
Tejon, P. [10 ]
Pena, S. [11 ]
Adan, A. [2 ]
Sanmarti, R. [1 ]
机构：
[1] Hosp Clin Barcelona, Rheumatol, Barcelona, Spain
[2] Hosp Clin Barcelona, Ophtalmol, Barcelona, Spain
[3] Hosp Marques de Valdecilla, Rheumatol, Santander, Spain
[4] Hosp Univ Donostia, Rheumatol, San Sebastian, Spain
[5] Hosp Univ Donostia, Ophtalmol, San Sebastian, Spain
[6] Hosp Can Misses, Rheumatol, Ibiza, Spain
[7] Txagorritxu Hosp, Rheumatol, Vitoria, Spain
[8] Hosp Univ Infanta Elena, Rheumatol, Madrid, Spain
[9] Complejo Hosp Univ Albacete, Rheumatol, Albacete, Spain
[10] Hosp Univ Gen Castellon, Rheumatol, Castellon de La Plana, Spain
[11] Hosp Univ Gen Castellon, Ophtalmol, Castellon de La Plana, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.4425
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0381
引用
收藏
页码：350 / 350
页数：1
相关论文
共 50 条
  • [21] Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
    Lindstrom, Ulf
    Bengtsson, Karin
    Olofsson, Tor
    Di Giuseppe, Daniela
    Glintborg, Bente
    Forsblad-d'Elia, Helena
    Jacobsson, Lennart T. H.
    Askling, Johan
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (11) : 1445 - 1452
  • [22] The Cytotoxic Effects of Certolizumab Pegol and Golimumab Mediated by Transmembrane Tumor Necrosis Factor α
    Ueda, Naoyasu
    Tsukamoto, Hiroshi
    Mitoma, Hiroki
    Ayano, Masahiro
    Tanaka, Atsushi
    Ohta, Shun-ichiro
    Inoue, Yasushi
    Arinobu, Yojiro
    Niiro, Hiroaki
    Akashi, Koichi
    Horiuchi, Takahiko
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (06) : 1224 - 1231
  • [23] Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis.
    Rosenbaum, James T.
    Rudwaleit, Martin
    Landewe, Robert B. M.
    Marzo-Ortega, Helena
    Sieper, Joachim
    van der Heijde, Desiree M.
    Davies, Owen
    Stach, Christian
    Nurminen, Tommi
    Deodhar, Atul A.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S237 - S237
  • [24] Tumour necrosis factor inhibitors
    Hill, Catherine L.
    Nash, Peter
    AUSTRALIAN PRESCRIBER, 2008, 31 (03) : 61 - 61
  • [25] Tumour necrosis factor inhibitors
    Nash, PT
    Florin, THJ
    MEDICAL JOURNAL OF AUSTRALIA, 2005, 183 (04) : 205 - 208
  • [26] Exploring sub-optimal response to tumour necrosis factor inhibitors in axial spondyloarthritis
    Yahya, Fariz
    Gaffney, Karl
    Sengupta, Raj
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2019, 3 (01)
  • [27] EXPLORING SUB-OPTIMAL RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS IN AXIAL SPONDYLOARTHRITIS
    Yahya, F.
    Gaffney, K.
    Sengupta, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 723 - 723
  • [28] CERTOLIZUMAB PEGOL IS EFFECTIVE IN CHILDREN WITH JIA NOT RESPONSIVE TO OTHER TNF ALPHA ANTAGONISTS
    Tzaribachev, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 435 - 435
  • [29] Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis: a proof-of-concept study
    Wittoek, Ruth
    Carron, Philippe
    Lambert, Bieke
    Meersseman, Paulien
    Verbruggen, Gust
    Van den Bosch, Filip
    Elewaut, Dirk
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (02) : 310 - 311
  • [30] MULTICENTER STUDY OF 71 PATIENTS WITH REFRACTORY UVEITIS RELATED TO IMMUNEMEDIATED INFLAMMATORY DISEASES ON CERTOLIZUMAB PEGOL TREATMENT
    Martin-Varillas, J. L.
    Calvo-Rio, V.
    Sanchez-Bilbao, L.
    Gonzalez-Mazon, I.
    Adan, A.
    Hernanz Rodriguez, I.
    Gallego, A.
    Beltran, E.
    Castro, S.
    Fanlo, P.
    Garcia Martos, A.
    Torre-Salaberri, I.
    Cordero-Coma, M.
    De Dios-Jimenez Aberasturi, J.
    Garcia-Aparicio, A.
    Hernandez-Garfella, M.
    Sanchez-Andrade, A.
    Garcia-Valle, A.
    Maiz, O.
    Miguelez, R.
    Rodriguez Montero, S.
    Urruticoechea-Arana, A.
    Veroz Gonzalez, R.
    Conesa, A.
    Fernandez-Carballido, C.
    Jovani, V.
    Martinez Gonzalez, O.
    Moya, P.
    Romero-Yuste, S.
    Rubio Munoz, P.
    Pena Sainz-Pardo, E.
    Gonzalez-Gay, M. A.
    Hernandez, J. L.
    Blanco, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 952 - 952
12345